Impact of early refined nursing program on prognosis of middle-aged and elderly patients with cognitive dysfunction combined with cerebral infarction

Table 1 Comparison of demographic data between the two groups, n (%)/mean ± SD

Item	Experimental group (n = 32)	Control group (n = 28)	t/χ2/Z	P value
Age (yr)	59.45 ± 3.94	59.87 ± 4.40	0.390	0.697
Gender			0.765	0.381
Man	17 (53.13)	18 (64.29)
Woman	15 (46.87)	10 (35.71)
BMI (kg/m²)	24.88 ± 3.62	24.01 ± 3.27	0.971	0.335
Smoking history	13 (40.63)	12 (42.85)	0.030	0.861
Drinking history	5 (15.62)	6 (21.42)	0.335	0.561
Side of lesion			2.116	0.145
Left side	17 (53.13)	20 (71.43)
Right side	15 (46.87)	8 (28.57)
Education background			1.558	0.119
Junior high school and below	24 (75.00)	16 (57.14)
Senior high school	6 (18.75)	7 (25.00)
College and above	2 (6.25)	5 (17.86)
History of hypertension	23 (71.87)	19 (67.85)	0.114	0.734
History of coronary heart disease	4 (12.50)	3 (10.71)	0.035	0.850
History of atrial fibrillation	5 (15.62)	2 (7.14)	0.381	0.536

Table 2 Changes in Mini-Mental State Examination and Trail Making Test scores, mean ± SD

Item	Time (wk)	Experimental group (n = 32)	Control group (n = 28)	Inter-group comparison (F/P value)	Time comparison (F/P value)	Inter-group time interactive comparison (F/P value)
MMSE score	0	18.45 ± 3.52	18.84 ± 4.74	9.451/0.002	37.030/< 0.001	4.395/0.013
	6	21.69 ± 3.24a,b	19.32 ± 3.05b
	12	25.26 ± 2.38a,b	22.12 ± 2.19b
TMT-A score	0	82.35 ± 12.84	81.66 ± 14.57	9.016/0.003	193.200/< 0.001	3.664/0.027
	6	61.58 ± 10.25a,b	71.34 ± 11.46b
	12	41.59 ± 5.32a,b	46.75 ± 5.87b
TMT-B score	0	162.18 ± 45.25	163.36 ± 42.16	5.332/0.022	57.420/< 0.001	1.151/0.318
	6	123.73 ± 23.11a,b	141.39 ± 22.96b
	12	96.76 ± 16.33a,b	109.42 ± 19.86b

^aP < 0.05 compared with control group.

^bP < 0.05 compared with 0 wk.

MMSE: Mini-Mental State Scale; TMT: Trail Making Test.

Table 3 Changes in the latency and amplitude of P300, mean ± SD

Group	Latency (ms)			Amplitude (μv)
	0 wk	6 wk	12 wk	0 wk	6 wk	12 wk
Experimental group (n = 32)	452.38 ± 40.52	402.31 ± 21.14a,b	365 ± 15.13a,b	4.53 ± 2.14	6.18 ± 1.74a,b	6.89 ± 1.45a,b
Control group (n = 28)	467.84 ± 43.99	437.79 ± 22.57b	384.23 ± 16.46b	4.41 ± 2.08	5.22 ± 1.93b	6.02 ± 1.66b
Inter-group comparison (F/P value)	30.340/< 0.001			5.556/0.019
Time comparison (F/P value)	136.700/< 0.001			17.600/< 0.001
Inter-group time interactive comparison (F/P value)	2.179/0.116			0.932/0.395

^aP < 0.05 compared with control group.

^bP < 0.05 compared with 0 wk.

Table 4 Changes in growth factors, mean ± SD

Item	Time (wk)	Experimental group (n = 32)	Control group (n = 28)	Inter-group comparison (F/P value)	Time comparison (F/P value)	Inter-group time interactive comparison (F/P value)
BNDF (ng/mL)	0	4.85 ± 0.79	4.92 ± 0.83	19.330/< 0.001	146.100/< 0.001	9.113/< 0.001
	6	6.63 ± 1.05a,b	6.07 ± 0.86b
	12	8.77 ± 1.25a,b	7.28 ± 1.14b
TGF-β1 (ng/L)	0	15.42 ± 2.54	15.68 ± 2.99	19.080/< 0.001	92.220/< 0.001	8.759/< 0.001
	6	20.44 ± 3.12a,b	18.56 ± 3.08b
	12	25.71 ± 3.52a,b	21.13 ± 3.66b
GDNF (pg/mL)	0	288.61 ± 25.26	282.74 ± 24.18	40.080/< 0.001	157.200/< 0.001	6.016/0.003
	6	346.59 ± 25.84a,b	312.72 ± 26.38b
	12	392.27 ± 29.96a,b	355.06 ± 30.47b

^aP < 0.05 compared with control group.

^bP < 0.05 compared with 0 wk.